Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joerg Albrecht

Showing results (1-10 of 49) with videos related to

Pageof 5
Sort By:
The British Journal of Dermatology|November 25, 2024
A reassuringly routine trialJoerg Albrecht
JAMA Dermatology|May 25, 2022
The Power of Topical SteroidsJoerg Albrecht
JAMA Dermatology|May 21, 2015
The Reach of the 340B Drug Pricing ProgramJoerg Albrecht, Sukhraj Mudahar
Journal of the American Academy of Dermatology|January 11, 2003
The meaning of "safe and effective"Joerg Albrecht, Michael Bigby
The British Journal of Dermatology|August 25, 2018
Put the ducks in a row - which biologic to use first?Joerg Albrecht, Sascha Gerdes
Journal of the American Academy of Dermatology|October 1, 2019
Rifampin and clindamycin are safe long-term: Response to "North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations Part II: Topical, intralesional, and systemic medical management"Joerg Albrecht, Michael Bigby
Archives of Dermatology|April 13, 2011
Testing a test: critical appraisal of tests for diagnosing scabiesJoerg Albrecht, Michael Bigby
The British Journal of Dermatology|April 4, 2022
Another anti-interleukin (IL)-17 inhibitor: is there an advantage of blocking IL-17A and IL-17F?Sascha Gerdes, Joerg Albrecht
Archives of Dermatology|March 21, 2012
Practice Gaps. Improving the care of our patients who are receiving glucocorticoid therapyJoerg Albrecht, Victoria P Werth
Dermatologic Therapy|June 1, 2007
Development of the CLASI as an outcome instrument for cutaneous lupus erythematosusJoerg Albrecht, Victoria P Werth
Pageof 5

Showing results (1-10 of 49) with videos related to

Sort By:
Pageof 5
The British Journal of Dermatology|November 25, 2024
A reassuringly routine trialJoerg Albrecht
JAMA Dermatology|May 25, 2022
The Power of Topical SteroidsJoerg Albrecht
JAMA Dermatology|May 21, 2015
The Reach of the 340B Drug Pricing ProgramJoerg Albrecht, Sukhraj Mudahar
Journal of the American Academy of Dermatology|January 11, 2003
The meaning of "safe and effective"Joerg Albrecht, Michael Bigby
The British Journal of Dermatology|August 25, 2018
Put the ducks in a row - which biologic to use first?Joerg Albrecht, Sascha Gerdes
Journal of the American Academy of Dermatology|October 1, 2019
Rifampin and clindamycin are safe long-term: Response to "North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations Part II: Topical, intralesional, and systemic medical management"Joerg Albrecht, Michael Bigby
Archives of Dermatology|April 13, 2011
Testing a test: critical appraisal of tests for diagnosing scabiesJoerg Albrecht, Michael Bigby
The British Journal of Dermatology|April 4, 2022
Another anti-interleukin (IL)-17 inhibitor: is there an advantage of blocking IL-17A and IL-17F?Sascha Gerdes, Joerg Albrecht
Archives of Dermatology|March 21, 2012
Practice Gaps. Improving the care of our patients who are receiving glucocorticoid therapyJoerg Albrecht, Victoria P Werth
Dermatologic Therapy|June 1, 2007
Development of the CLASI as an outcome instrument for cutaneous lupus erythematosusJoerg Albrecht, Victoria P Werth
Pageof 5